Thereafter, the liver enzyme levels returned to the baseline without clinical sequelae, regardless of whether or not the drug was continued, with a median to normalization of 129 days reported from Thrive III.28 In a post-hoc analysis,29 the following risk factors for ALT elevation were identified: treatment of acute coronary syndrome, treatment for acute VTE, female, low body mass index (< 27), and concomitant use of statins. The gene discussed is GPT; the disease is acute coronary syndrome.